{"id":62681,"date":"2026-02-21T01:06:14","date_gmt":"2026-02-21T00:06:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/"},"modified":"2026-02-21T01:06:14","modified_gmt":"2026-02-21T00:06:14","slug":"neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/","title":{"rendered":"NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026"},"content":{"rendered":"
\n

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. The company\u2019s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).<\/p>\n

<\/a>
<\/a><\/p>\n

\nInvestors interested in listening to the conference call may do so by accessing a live webcast of the event here<\/a>. Individuals interested in participating in the call via telephone may access the call by dialing + 1 (800) 715-9871 and referencing Conference ID 8467256. The webcast will be archived on the company\u2019s investor relations website at https:\/\/investors.neuropace.com\/news-and-events\/events<\/a> and will be available for replay for at least 90 days after the event.<\/p>\n

\nAbout NeuroPace, Inc.<\/b><\/p>\n

\nBased in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:<\/b>
Scott Schaper
\n
Head of Investor Relations
\n
sschaper@neuropace.com<\/a>
investors@neuropace.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. The company\u2019s management will webcast a corresponding conference call beginning at 1:30 p.m. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62681","6":"format-standard","7":"category-industry"},"yoast_head":"\nNeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. The company\u2019s management will webcast a corresponding conference call beginning at 1:30 p.m. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-21T00:06:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260220564571\/en\/2726444\/22\/NeuroPace-logo-fullColor-rgb-small.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026\",\"datePublished\":\"2026-02-21T00:06:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\\\/\"},\"wordCount\":254,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260220564571\\\/en\\\/2726444\\\/22\\\/NeuroPace-logo-fullColor-rgb-small.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\\\/\",\"name\":\"NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260220564571\\\/en\\\/2726444\\\/22\\\/NeuroPace-logo-fullColor-rgb-small.jpg\",\"datePublished\":\"2026-02-21T00:06:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260220564571\\\/en\\\/2726444\\\/22\\\/NeuroPace-logo-fullColor-rgb-small.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260220564571\\\/en\\\/2726444\\\/22\\\/NeuroPace-logo-fullColor-rgb-small.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/","og_locale":"en_US","og_type":"article","og_title":"NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026 - Pharma Trend","og_description":"MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. The company\u2019s management will webcast a corresponding conference call beginning at 1:30 p.m. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/","og_site_name":"Pharma Trend","article_published_time":"2026-02-21T00:06:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260220564571\/en\/2726444\/22\/NeuroPace-logo-fullColor-rgb-small.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026","datePublished":"2026-02-21T00:06:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/"},"wordCount":254,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260220564571\/en\/2726444\/22\/NeuroPace-logo-fullColor-rgb-small.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/","url":"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/","name":"NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260220564571\/en\/2726444\/22\/NeuroPace-logo-fullColor-rgb-small.jpg","datePublished":"2026-02-21T00:06:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260220564571\/en\/2726444\/22\/NeuroPace-logo-fullColor-rgb-small.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260220564571\/en\/2726444\/22\/NeuroPace-logo-fullColor-rgb-small.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/neuropace-to-report-fourth-quarter-2025-financial-results-on-march-3-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62681"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62681\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}